Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight.

Plain Language Summary

Secondary analysis from the phase 2 retatrutide RCT examining associations between patient-reported eating behaviors (hunger, appetite, food cravings, control over eating) and weight loss outcomes. Identified which behavioral patterns predicted greater weight reduction with retatrutide versus placebo, providing mechanistic insights into how triple agonism of GLP-1R, GIPR, and GCGR affects appetite regulation and eating behavior in obesity treatment.